Artelo Biosciences (ARTL) Price & Analysis

Compare

539 Followers

ARTL Stock Chart & Stats

$1.80

-$0.05(-4.59%)

At close: Jan 08 4:00 PM EST

$1.80

-$0.05(-4.59%)

Day’s Range― - ―

52-Week Range$1.52 - $28.60

Previous CloseN/A

Volume8.82K

Average Volume (3M)89.20K

Market Cap

$2.13M

Enterprise Value$6.43M

Total Cash (Recent Filing)$2.07M

Total Debt (Recent Filing)$896.00K

Price to Earnings (P/E)―

Beta0.22

Next Earnings

Apr 01, 2026

EPS Estimate

-1.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.97

Shares Outstanding1,145,635

10 Day Avg. Volume70,584

30 Day Avg. Volume89,202

Financial Highlights & Ratios

PEG Ratio0.73

Price to Book (P/B)7.17

Price to Sales (P/S)0.00

P/FCF Ratio-2.45

Enterprise Value/Market Cap3.02

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.61

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical MilestonesArtelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.

Investigational DrugART27.13 is emerging as a high-value investigational drug, as no therapies have proven to be safe treatments and approved for cancer-related cachexia.

Bears Say

Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.

Artelo Biosciences News

Artelo Biosciences announces publication of research on SBFI103

Artelo Biosciences (ARTL) announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor...

24h ago

ARTL

Artelo Biosciences downgraded to Hold from Buy at Maxim

Maxim analyst Jason McCarthy downgraded Artelo Biosciences (ARTL) to Hold from Buy. Published first on TheFly – the...

15d ago

ARTL

Artelo Biosciences files to sell 899,972 shares of common stock for holders

16:57 EST Artelo Biosciences (ARTL) files to sell 899,972 shares of common stock for holders Published first on...

17d ago

ARTL

Artelo Biosciences reports Q3 EPS ($3.97) vs ($2.10) last year

“We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to...

22d ago

ARTL

Artelo Biosciences publishes peer-review article on fatty acid binding proteins

Artelo Biosciences (ARTL) announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein...

30d ago

ARTL

Artelo Biosciences Appeals Nasdaq Delisting Decision

The latest announcement is out from Artelo Biosciences ( ($ARTL) ). On November 19, 2025, Artelo Biosciences received...

9d ago

ARTL

Artelo Biosciences Reports Increased Losses Amid R&D Investments

Artelo Biosciences ( ($ARTL) ) has released its Q3 earnings. Here is a breakdown of the information Artelo...

16d ago

ARTL

Artelo Biosciences Revises Bylaws, Alters Governance Structure

Artelo Biosciences ( ($ARTL) ) has issued an announcement. On November 10, 2025, Artelo Biosciences, Inc. announced changes...

20d ago

ARTL

Artelo Biosciences Strengthens Financial Position with New Agreement

An update from Artelo Biosciences ( ($ARTL) ) is now available. On October 28, 2025, Artelo Biosciences entered...

1M ago

ARTL

Artelo Biosciences Appoints New Chief Financial Officer

Artelo Biosciences ( ($ARTL) ) has provided an announcement. On October 26, 2025, Artelo Biosciences announced the appointment...

1M ago

ARTL

Artelo Biosciences appoints Mark Spring as Chief Financial Officer

Artelo Biosciences (ARTL) announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025....

1M ago

ARTL

Artelo Biosciences Enters Cooperation Agreement with Farb

An update from Artelo Biosciences ( ($ARTL) ) is now available. On October 15, 2025, Artelo Biosciences entered...

2M ago

ARTL

Artelo announces expanded clinical data to be presented on ART26.12, ART27.13

Artelo Biosciences (ARTL) announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, is presenting...

2M ago

ARTL

Artelo prices 441,210 shares at $4.40 in underwritten public offering

Artelo Biosciences (ARTL) announced the pricing of its previously announced underwritten public offering of 441,210 shares of its...

2M ago

ARTL

ARTL FAQ

What was Artelo Biosciences Inc’s price range in the past 12 months?

Artelo Biosciences Inc lowest stock price was $1.52 and its highest was $28.60 in the past 12 months.

What is Artelo Biosciences Inc’s market cap?

Artelo Biosciences Inc’s market cap is $2.13M.

When is Artelo Biosciences Inc’s upcoming earnings report date?

Artelo Biosciences Inc’s upcoming earnings report date is Apr 01, 2026 which is in 118 days.

How were Artelo Biosciences Inc’s earnings last quarter?

Artelo Biosciences Inc released its earnings results on Nov 12, 2025. The company reported -$3.97 earnings per share for the quarter, missing the consensus estimate of -$0.82 by -$3.15.

Is Artelo Biosciences Inc overvalued?

According to Wall Street analysts Artelo Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Artelo Biosciences Inc pay dividends?

Artelo Biosciences Inc does not currently pay dividends.

What is Artelo Biosciences Inc’s EPS estimate?

Artelo Biosciences Inc’s EPS estimate is -1.57.

How many shares outstanding does Artelo Biosciences Inc have?

Artelo Biosciences Inc has 1,145,635 shares outstanding.

What happened to Artelo Biosciences Inc’s price movement after its last earnings report?

Artelo Biosciences Inc reported an EPS of -$3.97 in its last earnings report, missing expectations of -$0.82. Following the earnings report the stock price went down -8.163%.

Which hedge fund is a major shareholder of Artelo Biosciences Inc?

Currently, no hedge funds are holding shares in ARTL

Company Description

Artelo Biosciences Inc

Artelo Biosciences (ARTL) is a biopharmaceutical company focused on the development and commercialization of proprietary therapeutics targeting lipid signaling pathways, including the endocannabinoid system. The company operates in the biotechnology sector and is engaged in creating a diverse pipeline of products aimed at treating cancer, pain, and other serious medical conditions. Artelo's core products are in various stages of development, leveraging novel approaches to modulate the body's response to disease.

Artelo Biosciences (ARTL) Earnings & Revenues

Historic Earnings Reports

ARTL Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.1,2.8615384615384616,2.623076923076923,2.3846153846153846,2.146153846153846,1.9076923076923078,1.6692307692307693,1.4307692307692308,1.1923076923076923,0.953846153846154,0.7153846153846155,0.476923076923077,0.2384615384615385,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.1,2.8615384615384616,2.623076923076923,2.3846153846153846,2.146153846153846,1.9076923076923078,1.6692307692307693,1.4307692307692308,1.1923076923076923,0.953846153846154,0.7153846153846155,0.476923076923077,0.2384615384615385,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.1,2.8615384615384616,2.623076923076923,2.3846153846153846,2.146153846153846,1.9076923076923078,1.6692307692307693,1.4307692307692308,1.1923076923076923,0.953846153846154,0.7153846153846155,0.476923076923077,0.2384615384615385,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.22,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >